<DOC>
	<DOCNO>NCT01548820</DOCNO>
	<brief_summary>On treatment parameter Lamivudine resistance HBV treat Egyptian patient</brief_summary>
	<brief_title>Resistance Lamivudine HBV Egyptian Patients</brief_title>
	<detailed_description>Primarily : To study correlation follow parameter adult Egyptian patient chronic viral hepatitis B treatment : - ALT . - HBeAg . - HBV-DNA quantitative PCR . - Biopsy ( possible ) . Secondarily : After receive lamivudine therapy identify impact parameter viral breakthrough 1 year therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adult patient &gt; 18 year old Egyptian nationality Positive serology HBsAg 6 month Positive HBV viremia ( 2000IU/ml ) . Lamivudine monotherapy AntiHBcIgM seropositivity Positive serology HCV Positive serology HDV Patients complicate HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Hepatitis B virus</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Resistance treatment</keyword>
</DOC>